← Home / Ernexa Therapeutics Inc. (ERNA)
Stock Analysis
Ernexa Therapeutics Inc. (ERNA)
ERNA
ERNA · Market data
4.22 -3.21%
Track ERNA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ERNA price is:
52W Range Position
2%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-09 19:33 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
5.78
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
26
●
Management / Board
MEDIUM
ERNA board and management update
On June 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”), delivered her notice of resignation, with such resignation becoming effective July 3, 2026.
8-K Filing • SEC EDGAR
What's Driving ERNA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.78 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
DT Break
fresh (age 1)
RSI(14)
42.8
◎
How to read this setup
Fresh structural signal: downtrend break age is 1 bars, so the breakout is still relatively recent.
Price Chart
ERNA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-07
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$4.9M
Company size
EV
$2.9M
Debt-adjusted value
P/E
-0.4
Not meaningful
P/S
8.5
Balanced
P/B
0.7
Low book multiple
EV/Sales
4.9
Balanced
EV/EBIT
-0.2
Not meaningful
P/FCF
-0.7
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
💵 Revenue
487,000
↘ Weak
📈 Net Income
-5.51M
↘ Negative
🧮 EPS (Basic)
-6.95
↘ Negative
Ernexa Therapeutics Inc.
Related Opportunities